US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ZYVERSA THERAPEUTICS INC

0.6398

-0.0151-2.31%

Volume:405.42K

Turnover:255.71K

Market Cap:3.05M

PE:-0.08

High:0.6500

Open:0.6311

Low:0.6100

Close:0.6549

Loading ...

Overview Company News Filings

Zyversa Therapeutics Faces Potential Nasdaq Delisting Due to Bid Price Non-Compliance

Press Release: ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

BRIEF-ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity

Zyversa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination With Glp-1 Agonists to Address Unmet Medical Needs of People Living With Obesity; Provides R&D Update

THOMSON REUTERS

BRIEF-Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation

Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor Ic 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease

THOMSON REUTERS

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease

BRIEF-ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status

Zyversa Therapeutics CEO Issues Shareholder Letter on Parasol Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (Fsgs)

THOMSON REUTERS

Zyversa Therapeutics: Initiating Small Phase 2a Proof-of-Concept Trial With Var 200 in First Half of 2025 in Patients With Dkd

THOMSON REUTERS

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)

ZyVersa Therapeutics files to sell 4.21M shares of common stock for holders

ZyVersa Therapeutics FY24 EPS $(8.48) Up From $(1,089.70) YoY

Press Release: ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

ZyVersa Therapeutics prices 2.1M shares at 95c in private placement

Zyversa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced at the Market

THOMSON REUTERS

ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition

BRIEF-Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ZVSA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZVSA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZVSA\",,,,,undefined,":{"symbol":"ZVSA","market":"US","secType":"STK","nameCN":"ZYVERSA THERAPEUTICS INC","latestPrice":0.6398,"timestamp":1749499200000,"preClose":0.6549,"halted":0,"volume":405416,"delay":0,"floatShares":3613500,"shares":4773456,"eps":-8.480319,"marketStatus":"Pre-Mkt","change":-0.0151,"latestTime":"06-10 04:06:50 EDT","open":0.6311,"high":0.65,"low":0.61,"amount":255713.8716704,"amplitude":0.061078,"askPrice":0.799,"askSize":956,"bidPrice":0.58,"bidSize":700,"shortable":3,"etf":0,"ttmEps":-8.480319,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749562200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.6398,"postHourTrading":{"tag":"盘后","latestPrice":0.63,"preClose":0.6398,"latestTime":"19:58 EDT","volume":19928,"amount":12674.1058,"timestamp":1749513530374},"volumeRatio":0.2964417137438545},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZVSA\",,,,,undefined,":{"symbol":"ZVSA","floatShares":3613500,"roa":"-24.79%","roe":"-91.39%","lyrEps":-8.480319,"volumeRatio":0.2964417137438545,"shares":4773456,"dividePrice":0,"high":0.65,"amplitude":0.061078,"preClose":0.6549,"low":0.61,"week52Low":0.4728,"pbRate":"0.38","week52High":6.3,"institutionHeld":0,"latestPrice":0.6398,"committee":-0.154589,"eps":-8.480319,"divideRate":0,"volume":405416,"delay":0,"ttmEps":-8.480319,"open":0.6311,"prevYearClose":1.06,"prevWeekClose":0.6549,"prevMonthClose":0.6274,"prevQuarterClose":0.6286,"fiveDayClose":0.6563,"twentyDayClose":0.5272,"sixtyDayClose":0.801},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZVSA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539270274","title":"Zyversa Therapeutics Faces Potential Nasdaq Delisting Due to Bid Price Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2539270274","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539270274?lang=en_us&edition=fundamental","pubTime":"2025-05-31 04:16","pubTimestamp":1748636180,"startTime":"0","endTime":"0","summary":"Zyversa Therapeutics Inc. has announced it received a Minimum Bid Price Deficiency Letter from The Nasdaq Capital Market Stock Exchange on May 27, 2025. The notice indicates the company's common stock had a closing bid price below $1.00 for 30 consecutive business days, placing it in non-compliance with Listing Rule 5550. Typically, companies have a 180-day period to regain compliance; however, Zyversa is not eligible for this due to two reverse stock splits within the past two years, including a 1-for-35 reverse split in December 2023 and a 1-for-10 reverse split in April 2024. Zyversa plans to appeal the decision and request a hearing before a panel, which will temporarily halt any suspension or delisting actions pending the panel's decision. The company must submit its appeal by June 3, 2025, to prevent its securities from being delisted on June 5, 2025. There is no guarantee that Zyversa will meet the necessary requirements for continued listing on the Nasdaq Capital Market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL5drM9w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2535178443","title":"Press Release: ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2535178443","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535178443?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:35","pubTimestamp":1747082100,"startTime":"0","endTime":"0","summary":"-- First patient expected to start therapy by end of Q2-2025 in Phase 2a. proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200. with Inflammasome ASC Inhibitor IC 100 planned to begin by end of. -- Investigational New Drug Application  for IC 100 anticipated to be. submitted H2-2025, followed by initiation of a Phase 1 clinical trial in. healthy overweight subjects at risk of cardiometabolic diseases.-- Groundbreaking data demonstrating IC 100 blocks microglial inflammasome. activation and reduces neurotoxic alpha-synuclein accumulation -- both. progression -- recently published (study sponsored by Michael J. Fox. -- Invited MJFF grant request submitted for funding PD animal model. WESTON, Fla., May 12, 2025  -- ZyVersa Therapeutics, Inc. , a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for the quarter ended March 31, 2","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LENZ","TM","03160","BK4007","BK4588","BK4604","LU1169590202.USD","ZVSA","LU1169589451.USD","BK4539","BK4585","BK4023","BK4099","BK4139","LU2065732104.USD","PRGS","BK4097","BK4555"],"gpt_icon":0},{"id":"2533984508","title":"BRIEF-ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2533984508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533984508?lang=en_us&edition=fundamental","pubTime":"2025-05-07 19:59","pubTimestamp":1746619172,"startTime":"0","endTime":"0","summary":"BRIEF-ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity May 7 (Reuters) - Zyversa Therapeutics Inc ZVSA.O:ZYVERSA U","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nTUA4RSY26:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2533981206","title":"Zyversa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination With Glp-1 Agonists to Address Unmet Medical Needs of People Living With Obesity; Provides R&D Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533981206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533981206?lang=en_us&edition=fundamental","pubTime":"2025-05-07 19:57","pubTimestamp":1746619020,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nTUA4RSY26:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2531739814","title":"BRIEF-Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation","url":"https://stock-news.laohu8.com/highlight/detail?id=2531739814","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531739814?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:50","pubTimestamp":1745931028,"startTime":"0","endTime":"0","summary":"BRIEF-Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation April 29 (Reuters) - Zyversa Therapeutics Inc ZVSA.O:ZYVERSA ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA12JXSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2531873597","title":"Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor Ic 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2531873597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531873597?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:57","pubTimestamp":1745927820,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA12JXSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2531801387","title":"ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2531801387","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531801387?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:57","pubTimestamp":1745927820,"startTime":"0","endTime":"0","summary":"Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study.Parkinson’s Disease  affects over 10 million people globally and is driven by inflammation leading to progressive neurodegeneration resulting in impaired mobility, cognitive decline, and other neurological symptoms.WESTON, Fla., April 29, 2025  -- ZyVersa Therapeutics, Inc. , a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces newly published data supporting the potential of its Inflammasome ASC Inhibitor IC 100 to slow the progression of Parkinson’s disease.Published in npj Parkinson's Disease, a peer-reviewed journal from Nature, the study presents groundbreaking findings from researchers at the University of Miami Miller School of Medicine. The research demonstrates that IC 100 blocks microglial inflammas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zyversa-therapeutics-announces-published-data-115700776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","BK4139","PD","LU1169590202.USD","ASC","LU1169589451.USD","ZVSA","LENZ","FSGS","BK4007","BK4144"],"gpt_icon":0},{"id":"2529816929","title":"BRIEF-ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2529816929","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529816929?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:26","pubTimestamp":1745497586,"startTime":"0","endTime":"0","summary":"BRIEF-ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA836CC1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2525896963","title":"Zyversa Therapeutics CEO Issues Shareholder Letter on Parasol Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (Fsgs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525896963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525896963?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:57","pubTimestamp":1744113434,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM0TT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZVSA","BK4139"],"gpt_icon":0},{"id":"2525896957","title":"Zyversa Therapeutics: Initiating Small Phase 2a Proof-of-Concept Trial With Var 200 in First Half of 2025 in Patients With Dkd","url":"https://stock-news.laohu8.com/highlight/detail?id=2525896957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525896957?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:57","pubTimestamp":1744113434,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM0TT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZVSA","BK4139"],"gpt_icon":0},{"id":"2525894454","title":"ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525894454","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525894454?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:57","pubTimestamp":1744113420,"startTime":"0","endTime":"0","summary":"WESTON, Fla., April 08, 2025  -- ZyVersa Therapeutics, Inc. , a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a Shareholder Letter addressing the recent PARASOL recommendations expected to shorten drug development time and approval for rare kidney disease, FSGS. The full text of the letter follows.ZyVersa is developing Cholesterol Efflux MediatorVAR 200 for treatment of chronic kidney diseases, initially focusing on FSGS as the lead. Plans for indication expansion include treatments for Alport Syndrome and Diabetic Kidney Disease. The global drug market for kidney diseases was $18 Billion in 2024, with $30 Billion projected by 2034 .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zyversa-therapeutics-ceo-issues-shareholder-115700993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ZVSA","FSGS","LENZ","BK4007"],"gpt_icon":0},{"id":"2525753430","title":"ZyVersa Therapeutics files to sell 4.21M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2525753430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525753430?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:50","pubTimestamp":1743799808,"startTime":"0","endTime":"0","summary":"16:48 EDT ZyVersa Therapeutics (ZVSA) files to sell 4.21M shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zyversa-therapeutics-files-to-sell-4-21m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zyversa-therapeutics-files-to-sell-4-21m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","ZVSA"],"gpt_icon":0},{"id":"2522370306","title":"ZyVersa Therapeutics FY24 EPS $(8.48) Up From $(1,089.70) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2522370306","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522370306?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:18","pubTimestamp":1743081512,"startTime":"0","endTime":"0","summary":"ZyVersa Therapeutics FY24 EPS $(8.48) Up From $(1,089.70) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44514150/zyversa-therapeutics-fy24-eps-8-48-up-from-1-089-70-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZVSA","LENZ"],"gpt_icon":0},{"id":"2522050543","title":"Press Release: ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522050543","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522050543?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:15","pubTimestamp":1743081300,"startTime":"0","endTime":"0","summary":"-- Phase 2a proof-of concept clinical trial for Cholesterol Efflux. Mediator VAR 200 in patients with diabetic kidney disease . -- Regulatory path for VAR 200's lead indication, focal segmental. glomerulosclerosis , expected to be shorter based on FDA's. alignment with data supporting proteinuria reduction as a clinical. WESTON, Fla., March 27, 2025  -- ZyVersa Therapeutics, Inc. , a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for full year ending December 31, 2024, and provides business update.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","ZVSA","03160","BK4585","BK4139","BK4604","BK4588","BK4555","LENZ","BK4099","TM"],"gpt_icon":0},{"id":"2520670180","title":"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2520670180","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520670180?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:57","pubTimestamp":1742299020,"startTime":"0","endTime":"0","summary":"In obesity-associated cardiomyopathy , heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with congestive heart failure and sudden cardiac death predominant causes of death.Data showed that NLRP3 inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function.Data support the potential of ZyVersa’s Inflammasome ASC Inhibitor IC 100 as an effective treatment option for patients with obesity and its associated cardiovascular comorbidities.WESTON, Fla., March 18, 2025  -- ZyVersa Therapeutics, Inc. , a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published animal model data demonstrating that inflammasome inhibition attenuates obesity-associated cardiomyopathy, which has a 5-year survival rate <50%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zyversa-therapeutics-highlights-data-published-115700084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","AFG","ZVSA"],"gpt_icon":0},{"id":"2517202152","title":"ZyVersa Therapeutics prices 2.1M shares at 95c in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2517202152","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517202152?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:12","pubTimestamp":1741266744,"startTime":"0","endTime":"0","summary":"ZyVersa Therapeutics (ZVSA) has entered into a securities purchase agreement with a single healthcare-focused U.S. institutional investor for the p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zyversa-therapeutics-prices-2-1m-shares-at-95c-in-private-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zyversa-therapeutics-prices-2-1m-shares-at-95c-in-private-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZVSA","LENZ"],"gpt_icon":0},{"id":"2517154920","title":"Zyversa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced at the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2517154920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517154920?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:00","pubTimestamp":1741266015,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PP10R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZVSA","BK4139"],"gpt_icon":0},{"id":"2517919437","title":"ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition","url":"https://stock-news.laohu8.com/highlight/detail?id=2517919437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517919437?lang=en_us&edition=fundamental","pubTime":"2025-03-05 20:55","pubTimestamp":1741179355,"startTime":"0","endTime":"0","summary":"ZyVersa Therapeutics (ZVSA) highlights newly published data demonstrating cardioprotective effects and improvements in metabolic parameters with in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zyversa-therapeutics-highlights-data-on-nlrp3-inflammasome-inhibition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zyversa-therapeutics-highlights-data-on-nlrp3-inflammasome-inhibition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZVSA","LENZ","BK4139"],"gpt_icon":0},{"id":"2493408477","title":"BRIEF-Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2493408477","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493408477?lang=en_us&edition=fundamental","pubTime":"2024-12-21 06:12","pubTimestamp":1734732725,"startTime":"0","endTime":"0","summary":"BRIEF-Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC FilingZyversa Therapeutics Inc ZVSA.O:ZYVERSA THERAPEUTICS: FILES FOR PROSPECTUS RELATED TO OFFER & RESALE OF UP TO 1.6 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDER - SEC FILINGSource text: [ID:n0001493152-24-051094]Further company coverage: ZVSA.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nFWN3NL1HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZVSA"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZVSA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"ZVSA","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.73},{"date":"2025-03-27","symbol":"ZVSA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"Pre-Market","dateTimestamp":1743048000000,"actualEps":null},{"market":"US","date":"2024-11-14","symbol":"ZVSA","fiscalQuarterEnding":"2024/09","expectedEps":-5.8,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-2.43},{"market":"US","date":"2024-08-09","symbol":"ZVSA","fiscalQuarterEnding":"2024/06","expectedEps":-5.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":-3.31},{"market":"US","date":"2024-05-15","symbol":"ZVSA","fiscalQuarterEnding":"2024/03","expectedEps":-3.7,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"pre","actualEps":-4.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZVSA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZVSA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZVSA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZVSA","date":"2025-06-06","current":-0.348255,"percent":0.426966,"low":-21.281928,"twenty":-7.836338,"median":-0.216817,"eighty":-0.054599,"high":-0.009885,"avg":-2.621326,"sd":3.875151,"marketCap":3079838},"quantilePoints":[{"date":"2022-02-11","current":-7.527467,"twenty":-7.527467,"median":-7.527467,"eighty":-7.527467,"marketCap":95472110},{"date":"2022-02-18","current":-7.542751,"twenty":-7.542751,"median":-7.542751,"eighty":-7.527467,"marketCap":95665962},{"date":"2022-02-25","current":-7.542751,"twenty":-7.542751,"median":-7.542751,"eighty":-7.527467,"marketCap":95665962},{"date":"2022-03-04","current":-7.535109,"twenty":-7.542751,"median":-7.542751,"eighty":-7.535109,"marketCap":95569036},{"date":"2022-03-11","current":-7.550393,"twenty":-7.542751,"median":-7.542751,"eighty":-7.535109,"marketCap":95762888},{"date":"2022-03-18","current":-7.565677,"twenty":-7.550393,"median":-7.542751,"eighty":-7.535109,"marketCap":95956740},{"date":"2022-03-25","current":-7.603888,"twenty":-7.550393,"median":-7.542751,"eighty":-7.542751,"marketCap":96441370},{"date":"2022-04-01","current":-7.603888,"twenty":-7.565677,"median":-7.550393,"eighty":-7.542751,"marketCap":96441370},{"date":"2022-04-08","current":-7.603888,"twenty":-7.603888,"median":-7.550393,"eighty":-7.542751,"marketCap":96441370},{"date":"2022-04-14","current":-7.603888,"twenty":-7.603888,"median":-7.550393,"eighty":-7.542751,"marketCap":96441370},{"date":"2022-04-22","current":-7.852153,"twenty":-7.603888,"median":-7.558035,"eighty":-7.542751,"marketCap":99590164},{"date":"2022-04-29","current":-7.860061,"twenty":-7.603888,"median":-7.565677,"eighty":-7.542751,"marketCap":99690456},{"date":"2022-05-06","current":-7.867968,"twenty":-7.860061,"median":-7.603888,"eighty":-7.542751,"marketCap":99790748},{"date":"2022-05-13","current":-7.836338,"twenty":-7.860061,"median":-7.603888,"eighty":-7.542751,"marketCap":99389580},{"date":"2022-05-20","current":-7.875876,"twenty":-7.860061,"median":-7.603888,"eighty":-7.542751,"marketCap":99891041},{"date":"2022-05-27","current":-7.852153,"twenty":-7.860061,"median":-7.603888,"eighty":-7.542751,"marketCap":99590164},{"date":"2022-06-03","current":-7.875876,"twenty":-7.860061,"median":-7.603888,"eighty":-7.542751,"marketCap":99891041},{"date":"2022-06-10","current":-7.875876,"twenty":-7.867968,"median":-7.603888,"eighty":-7.547336,"marketCap":99891041},{"date":"2022-06-17","current":-7.836338,"twenty":-7.867968,"median":-7.603888,"eighty":-7.550393,"marketCap":99389580},{"date":"2022-06-24","current":-7.875876,"twenty":-7.867968,"median":-7.820523,"eighty":-7.550393,"marketCap":99891041},{"date":"2022-07-01","current":-7.836338,"twenty":-7.867968,"median":-7.836338,"eighty":-7.550393,"marketCap":99389580},{"date":"2022-07-08","current":-7.860061,"twenty":-7.867968,"median":-7.836338,"eighty":-7.550393,"marketCap":99690456},{"date":"2022-07-15","current":-7.875876,"twenty":-7.867968,"median":-7.844246,"eighty":-7.550393,"marketCap":99891041},{"date":"2022-07-22","current":-7.875876,"twenty":-7.874294,"median":-7.844246,"eighty":-7.550393,"marketCap":99891041},{"date":"2022-07-29","current":-7.875876,"twenty":-7.875876,"median":-7.850967,"eighty":-7.550393,"marketCap":99891041},{"date":"2022-08-05","current":-7.891691,"twenty":-7.875876,"median":-7.852153,"eighty":-7.55345,"marketCap":100091625},{"date":"2022-08-12","current":-10.347355,"twenty":-7.875876,"median":-7.852153,"eighty":-7.565677,"marketCap":100292210},{"date":"2022-08-19","current":-10.337007,"twenty":-7.875876,"median":-7.852153,"eighty":-7.565677,"marketCap":100191917},{"date":"2022-08-26","current":-10.337007,"twenty":-7.875876,"median":-7.852153,"eighty":-7.565677,"marketCap":100191917},{"date":"2022-09-02","current":-10.32666,"twenty":-7.875876,"median":-7.852153,"eighty":-7.573319,"marketCap":100091625},{"date":"2022-09-09","current":-10.347355,"twenty":-7.883783,"median":-7.860061,"eighty":-7.603888,"marketCap":100292210},{"date":"2022-09-16","current":-10.316312,"twenty":-7.891691,"median":-7.860061,"eighty":-7.603888,"marketCap":99991333},{"date":"2022-09-23","current":-10.357702,"twenty":-7.907506,"median":-7.860061,"eighty":-7.603888,"marketCap":100392502},{"date":"2022-09-30","current":-10.434782,"twenty":-10.316312,"median":-7.860061,"eighty":-7.603888,"marketCap":100191917},{"date":"2022-10-07","current":-10.445227,"twenty":-10.32666,"median":-7.860061,"eighty":-7.603888,"marketCap":100292210},{"date":"2022-10-14","current":-10.476563,"twenty":-10.32666,"median":-7.867968,"eighty":-7.603888,"marketCap":100593086},{"date":"2022-10-21","current":-10.497453,"twenty":-10.337007,"median":-7.867968,"eighty":-7.603888,"marketCap":100793671},{"date":"2022-10-28","current":-10.476563,"twenty":-10.337007,"median":-7.875876,"eighty":-7.603888,"marketCap":100593086},{"date":"2022-11-04","current":-10.507899,"twenty":-10.347355,"median":-7.875876,"eighty":-7.603888,"marketCap":100893963},{"date":"2022-11-11","current":-10.539234,"twenty":-10.357702,"median":-7.875876,"eighty":-7.603888,"marketCap":101194839},{"date":"2022-11-18","current":-10.586238,"twenty":-10.378397,"median":-7.875876,"eighty":-7.603888,"marketCap":101646154},{"date":"2022-11-25","current":-10.643686,"twenty":-10.434782,"median":-7.875876,"eighty":-7.603888,"marketCap":102197761},{"date":"2022-12-02","current":-10.654132,"twenty":-10.466118,"median":-7.875876,"eighty":-7.603888,"marketCap":102298054},{"date":"2022-12-09","current":-10.121425,"twenty":-10.466118,"median":-7.875876,"eighty":-7.603888,"marketCap":97183151},{"date":"2022-12-16","current":-2.562,"twenty":-10.466118,"median":-7.875876,"eighty":-7.603888,"marketCap":29243788},{"date":"2022-12-23","current":-1.710652,"twenty":-10.466118,"median":-7.875876,"eighty":-7.603888,"marketCap":19526132},{"date":"2022-12-30","current":-1.249174,"twenty":-10.453583,"median":-7.875876,"eighty":-7.603888,"marketCap":14258617},{"date":"2023-01-06","current":-1.281,"twenty":-10.441049,"median":-7.875876,"eighty":-7.580961,"marketCap":14621894},{"date":"2023-01-13","current":-2.752956,"twenty":-10.434782,"median":-7.875876,"eighty":-7.556507,"marketCap":31423450},{"date":"2023-01-20","current":-1.718609,"twenty":-10.434782,"median":-7.875876,"eighty":-7.550393,"marketCap":19616951},{"date":"2023-01-27","current":-1.670869,"twenty":-10.434782,"median":-7.875876,"eighty":-7.550393,"marketCap":19072036},{"date":"2023-02-03","current":-1.933435,"twenty":-10.434782,"median":-7.867968,"eighty":-7.542751,"marketCap":22069070},{"date":"2023-02-10","current":-1.607217,"twenty":-10.424337,"median":-7.867968,"eighty":-7.542751,"marketCap":18345482},{"date":"2023-02-17","current":-1.869782,"twenty":-10.381724,"median":-7.860061,"eighty":-7.536637,"marketCap":21342516},{"date":"2023-02-24","current":-1.702696,"twenty":-10.378397,"median":-7.860061,"eighty":-7.527467,"marketCap":19435313},{"date":"2023-03-03","current":-1.654956,"twenty":-10.357702,"median":-7.860061,"eighty":-4.265844,"marketCap":18890397},{"date":"2023-03-10","current":-1.670869,"twenty":-10.357702,"median":-7.860061,"eighty":-2.418782,"marketCap":19072036},{"date":"2023-03-17","current":-1.400348,"twenty":-10.357702,"median":-7.860061,"eighty":-2.060739,"marketCap":15984182},{"date":"2023-03-24","current":-1.734522,"twenty":-10.357702,"median":-7.852153,"eighty":-1.958179,"marketCap":19798589},{"date":"2023-03-31","current":-1.535609,"twenty":-10.357702,"median":-7.852153,"eighty":-1.869782,"marketCap":17528109},{"date":"2023-04-06","current":-1.400348,"twenty":-10.351494,"median":-7.852153,"eighty":-1.858643,"marketCap":15984182},{"date":"2023-04-14","current":-1.154538,"twenty":-10.347355,"median":-7.852153,"eighty":-1.802948,"marketCap":16305101},{"date":"2023-04-21","current":-1.141492,"twenty":-10.347355,"median":-7.852153,"eighty":-1.755336,"marketCap":16120863},{"date":"2023-04-28","current":-0.327576,"twenty":-10.347355,"median":-7.850967,"eighty":-1.734569,"marketCap":4626227},{"date":"2023-05-05","current":-0.37167,"twenty":-10.347355,"median":-7.844246,"eighty":-1.722141,"marketCap":5248953},{"date":"2023-05-12","current":-0.323359,"twenty":-10.347355,"median":-7.844246,"eighty":-1.702696,"marketCap":4566681},{"date":"2023-05-19","current":-0.244626,"twenty":-10.341146,"median":-7.836338,"eighty":-1.670869,"marketCap":3404726},{"date":"2023-05-26","current":-0.271366,"twenty":-10.337007,"median":-7.836338,"eighty":-1.65973,"marketCap":3776888},{"date":"2023-06-02","current":-0.595797,"twenty":-10.337007,"median":-7.82843,"eighty":-1.607217,"marketCap":8292357},{"date":"2023-06-09","current":-0.579813,"twenty":-10.337007,"median":-7.820523,"eighty":-1.591304,"marketCap":8069879},{"date":"2023-06-16","current":-0.561146,"twenty":-10.337007,"median":-7.603888,"eighty":-1.559478,"marketCap":7810081},{"date":"2023-06-23","current":-0.440415,"twenty":-10.337007,"median":-7.603888,"eighty":-1.529243,"marketCap":6129730},{"date":"2023-06-30","current":-0.430212,"twenty":-10.337007,"median":-7.603888,"eighty":-1.457635,"marketCap":5987729},{"date":"2023-07-07","current":-0.408107,"twenty":-10.332868,"median":-7.603888,"eighty":-1.400348,"marketCap":5680059},{"date":"2023-07-14","current":-0.425111,"twenty":-10.32666,"median":-7.603888,"eighty":-1.296913,"marketCap":5916728},{"date":"2023-07-21","current":-0.368996,"twenty":-10.32666,"median":-7.603888,"eighty":-1.261904,"marketCap":5135720},{"date":"2023-07-28","current":-0.313371,"twenty":-10.32666,"median":-7.603888,"eighty":-1.163669,"marketCap":4361521},{"date":"2023-08-04","current":-0.309309,"twenty":-10.32666,"median":-7.565677,"eighty":-1.141492,"marketCap":4304983},{"date":"2023-08-11","current":-0.307181,"twenty":-10.32666,"median":-7.558035,"eighty":-1.11801,"marketCap":4275368},{"date":"2023-08-18","current":-0.303699,"twenty":-10.32666,"median":-7.550393,"eighty":-1.058,"marketCap":4226907},{"date":"2023-08-25","current":-0.051589,"twenty":-10.32666,"median":-7.550393,"eighty":-0.57554,"marketCap":4665022},{"date":"2023-09-01","current":-0.048582,"twenty":-10.32666,"median":-7.550393,"eighty":-0.562665,"marketCap":4393153},{"date":"2023-09-08","current":-0.041989,"twenty":-10.32666,"median":-7.542751,"eighty":-0.558863,"marketCap":3796895},{"date":"2023-09-15","current":-0.060169,"twenty":-10.320451,"median":-7.542751,"eighty":-0.517114,"marketCap":5440931},{"date":"2023-09-22","current":-0.052281,"twenty":-10.316312,"median":-7.542751,"eighty":-0.441231,"marketCap":4727605},{"date":"2023-09-29","current":-0.060153,"twenty":-10.303896,"median":-7.542751,"eighty":-0.431743,"marketCap":5439425},{"date":"2023-10-06","current":-0.062896,"twenty":-10.295618,"median":-7.542751,"eighty":-0.424227,"marketCap":5687462},{"date":"2023-10-13","current":-0.06304,"twenty":-10.253773,"median":-7.535109,"eighty":-0.407903,"marketCap":5700517},{"date":"2023-10-20","current":-0.061644,"twenty":-10.163206,"median":-7.527467,"eighty":-0.38615,"marketCap":5574322},{"date":"2023-10-27","current":-0.055581,"twenty":-10.142315,"median":-7.523646,"eighty":-0.376992,"marketCap":5026028},{"date":"2023-11-03","current":-0.046534,"twenty":-8.35029,"median":-4.265844,"eighty":-0.362186,"marketCap":4207939},{"date":"2023-11-10","current":-0.035803,"twenty":-7.907506,"median":-2.657478,"eighty":-0.333478,"marketCap":3237545},{"date":"2023-11-17","current":-0.036701,"twenty":-7.907506,"median":-2.17213,"eighty":-0.328592,"marketCap":3289764},{"date":"2023-11-24","current":-0.040004,"twenty":-7.907506,"median":-2.068696,"eighty":-0.324245,"marketCap":3585846},{"date":"2023-12-01","current":-0.031557,"twenty":-7.898017,"median":-2.024935,"eighty":-0.316333,"marketCap":2828641},{"date":"2023-12-08","current":-0.015952,"twenty":-7.891691,"median":-1.958179,"eighty":-0.309502,"marketCap":1429861},{"date":"2023-12-15","current":-0.01023,"twenty":-7.891691,"median":-1.901609,"eighty":-0.307413,"marketCap":916976},{"date":"2023-12-22","current":-0.048692,"twenty":-7.886946,"median":-1.861826,"eighty":-0.30211,"marketCap":4364571},{"date":"2023-12-29","current":-0.055512,"twenty":-7.883783,"median":-1.857848,"eighty":-0.290163,"marketCap":4975946},{"date":"2024-01-05","current":-0.052962,"twenty":-7.883783,"median":-1.853869,"eighty":-0.285597,"marketCap":4747336},{"date":"2024-01-12","current":-0.047393,"twenty":-7.883783,"median":-1.802152,"eighty":-0.251536,"marketCap":4248168},{"date":"2024-01-19","current":-0.034922,"twenty":-7.879039,"median":-1.770326,"eighty":-0.072424,"marketCap":3130284},{"date":"2024-01-26","current":-0.038707,"twenty":-7.875876,"median":-1.750753,"eighty":-0.065177,"marketCap":3469529},{"date":"2024-02-02","current":-0.034243,"twenty":-7.875876,"median":-1.742518,"eighty":-0.062982,"marketCap":3069461},{"date":"2024-02-09","current":-0.03412,"twenty":-7.875876,"median":-1.734522,"eighty":-0.061606,"marketCap":3058450},{"date":"2024-02-16","current":-0.03374,"twenty":-7.875876,"median":-1.721553,"eighty":-0.060163,"marketCap":3024368},{"date":"2024-02-23","current":-0.036285,"twenty":-7.875876,"median":-1.710652,"eighty":-0.059241,"marketCap":3252454},{"date":"2024-03-01","current":-0.064345,"twenty":-7.875876,"median":-1.702696,"eighty":-0.0586,"marketCap":5767693},{"date":"2024-03-08","current":-0.080782,"twenty":-7.875876,"median":-1.674847,"eighty":-0.059241,"marketCap":7241014},{"date":"2024-03-15","current":-0.06769,"twenty":-7.875876,"median":-1.670869,"eighty":-0.060042,"marketCap":6067487},{"date":"2024-03-22","current":-0.069477,"twenty":-7.875876,"median":-1.658934,"eighty":-0.060153,"marketCap":6227737},{"date":"2024-03-28","current":-0.060072,"twenty":-7.875876,"median":-1.619152,"eighty":-0.060088,"marketCap":5904958},{"date":"2024-04-05","current":-0.057206,"twenty":-7.875876,"median":-1.599261,"eighty":-0.058057,"marketCap":5623190},{"date":"2024-04-12","current":-0.057947,"twenty":-7.875876,"median":-1.591304,"eighty":-0.057773,"marketCap":5696100},{"date":"2024-04-19","current":-0.048367,"twenty":-7.875876,"median":-1.559478,"eighty":-0.05663,"marketCap":4754345},{"date":"2024-04-26","current":-0.046937,"twenty":-7.875876,"median":-1.533619,"eighty":-0.055531,"marketCap":4613841},{"date":"2024-05-03","current":-0.044349,"twenty":-7.875876,"median":-1.495826,"eighty":-0.054896,"marketCap":4359415},{"date":"2024-05-10","current":-0.040795,"twenty":-7.875876,"median":-1.424376,"eighty":-0.05319,"marketCap":4010054},{"date":"2024-05-17","current":-0.037826,"twenty":-7.875876,"median":-1.400348,"eighty":-0.051973,"marketCap":3691072},{"date":"2024-05-24","current":-0.03339,"twenty":-7.875876,"median":-1.308848,"eighty":-0.051476,"marketCap":3258245},{"date":"2024-05-31","current":-0.031755,"twenty":-7.875876,"median":-1.292934,"eighty":-0.050906,"marketCap":3098678},{"date":"2024-06-07","current":-0.03697,"twenty":-7.875876,"median":-1.281,"eighty":-0.049989,"marketCap":3607530},{"date":"2024-06-14","current":-0.041742,"twenty":-7.875876,"median":-1.23334,"eighty":-0.049025,"marketCap":4073207},{"date":"2024-06-21","current":-0.041325,"twenty":-7.875876,"median":-1.167583,"eighty":-0.048602,"marketCap":4032547},{"date":"2024-06-28","current":-0.030973,"twenty":-7.875876,"median":-1.16106,"eighty":-0.048367,"marketCap":3022323},{"date":"2024-07-05","current":-0.030887,"twenty":-7.875876,"median":-1.141492,"eighty":-0.047431,"marketCap":3013974},{"date":"2024-07-12","current":-0.043208,"twenty":-7.875876,"median":-1.134969,"eighty":-0.046921,"marketCap":4216224},{"date":"2024-07-15","current":-0.041924,"twenty":-7.875876,"median":-1.128446,"eighty":-0.046855,"marketCap":4090990},{"date":"2024-08-02","current":-0.029261,"twenty":-7.875876,"median":-1.128446,"eighty":-0.046715,"marketCap":2855344},{"date":"2024-08-09","current":-0.025753,"twenty":-7.875876,"median":-1.108878,"eighty":-0.04506,"marketCap":2513036},{"date":"2024-08-16","current":-0.142372,"twenty":-7.875876,"median":-1.069741,"eighty":-0.045348,"marketCap":3108171},{"date":"2024-08-23","current":-0.142372,"twenty":-7.874294,"median":-0.579813,"eighty":-0.045816,"marketCap":3108171},{"date":"2024-08-30","current":-0.130115,"twenty":-7.867968,"median":-0.574291,"eighty":-0.046563,"marketCap":2840580},{"date":"2024-09-06","current":-0.132,"twenty":-7.867968,"median":-0.567606,"eighty":-0.04668,"marketCap":2881748},{"date":"2024-09-13","current":-0.105129,"twenty":-7.867968,"median":-0.561146,"eighty":-0.046855,"marketCap":2295107},{"date":"2024-09-20","current":-0.107014,"twenty":-7.867968,"median":-0.545154,"eighty":-0.046937,"marketCap":2336274},{"date":"2024-09-27","current":-0.108429,"twenty":-7.867968,"median":-0.494999,"eighty":-0.04713,"marketCap":2367150},{"date":"2024-10-04","current":-0.111201,"twenty":-7.860061,"median":-0.442115,"eighty":-0.047393,"marketCap":2427682},{"date":"2024-10-11","current":-0.11563,"twenty":-7.860061,"median":-0.437694,"eighty":-0.04744,"marketCap":2524360},{"date":"2024-10-18","current":-0.111201,"twenty":-7.860061,"median":-0.431488,"eighty":-0.047955,"marketCap":2427682},{"date":"2024-10-25","current":-0.101853,"twenty":-7.860061,"median":-0.426981,"eighty":-0.048002,"marketCap":2223585},{"date":"2024-10-31","current":-0.098959,"twenty":-7.860061,"median":-0.4229,"eighty":-0.048294,"marketCap":2160422},{"date":"2024-11-08","current":-0.07479,"twenty":-7.860061,"median":-0.412358,"eighty":-0.048539,"marketCap":1632777},{"date":"2024-11-15","current":-0.055601,"twenty":-7.860061,"median":-0.407596,"eighty":-0.048609,"marketCap":1213841},{"date":"2024-11-22","current":-0.057411,"twenty":-7.860061,"median":-0.384846,"eighty":-0.048677,"marketCap":1224583},{"date":"2024-11-29","current":-0.118021,"twenty":-7.860061,"median":-0.371269,"eighty":-0.048708,"marketCap":2517426},{"date":"2024-12-06","current":-0.113252,"twenty":-7.860061,"median":-0.366321,"eighty":-0.048948,"marketCap":2415688},{"date":"2024-12-13","current":-0.118692,"twenty":-7.860061,"median":-0.339908,"eighty":-0.049263,"marketCap":2531726},{"date":"2024-12-20","current":-0.136276,"twenty":-7.860061,"median":-0.332663,"eighty":-0.049654,"marketCap":2906796},{"date":"2024-12-27","current":-0.135177,"twenty":-7.856898,"median":-0.328846,"eighty":-0.049901,"marketCap":2883354},{"date":"2025-01-03","current":-0.119791,"twenty":-7.852153,"median":-0.327576,"eighty":-0.050145,"marketCap":2555168},{"date":"2025-01-10","current":-0.129682,"twenty":-7.852153,"median":-0.324836,"eighty":-0.050769,"marketCap":2766145},{"date":"2025-01-17","current":-0.148365,"twenty":-7.852153,"median":-0.320528,"eighty":-0.050891,"marketCap":3164657},{"date":"2025-01-24","current":-0.165949,"twenty":-7.852153,"median":-0.316323,"eighty":-0.050891,"marketCap":3539728},{"date":"2025-01-31","current":-0.151662,"twenty":-7.852153,"median":-0.310469,"eighty":-0.050903,"marketCap":3234983},{"date":"2025-02-07","current":-0.135726,"twenty":-7.852153,"median":-0.309502,"eighty":-0.051217,"marketCap":2895075},{"date":"2025-02-14","current":-0.14287,"twenty":-7.852153,"median":-0.307568,"eighty":-0.05144,"marketCap":3047448},{"date":"2025-02-21","current":-0.134078,"twenty":-7.852153,"median":-0.304393,"eighty":-0.051476,"marketCap":2859913},{"date":"2025-02-28","current":-0.128583,"twenty":-7.852153,"median":-0.301891,"eighty":-0.051476,"marketCap":2742703},{"date":"2025-03-07","current":-0.097811,"twenty":-7.852153,"median":-0.288309,"eighty":-0.051544,"marketCap":2086329},{"date":"2025-03-14","current":-0.08803,"twenty":-7.852153,"median":-0.285224,"eighty":-0.051753,"marketCap":1877696},{"date":"2025-03-21","current":-0.07704,"twenty":-7.852153,"median":-0.271366,"eighty":-0.051882,"marketCap":1643277},{"date":"2025-03-28","current":-0.076919,"twenty":-7.851441,"median":-0.246413,"eighty":-0.052127,"marketCap":1640699},{"date":"2025-04-04","current":-0.166148,"twenty":-7.850967,"median":-0.166148,"eighty":-0.052638,"marketCap":1564028},{"date":"2025-04-11","current":-0.210427,"twenty":-7.846934,"median":-0.172378,"eighty":-0.052911,"marketCap":1980845},{"date":"2025-04-17","current":-0.194413,"twenty":-7.844246,"median":-0.202243,"eighty":-0.052945,"marketCap":1830092},{"date":"2025-04-25","current":-0.195095,"twenty":-7.844246,"median":-0.193158,"eighty":-0.053044,"marketCap":1836513},{"date":"2025-05-02","current":-0.238005,"twenty":-7.844246,"median":-0.194754,"eighty":-0.053214,"marketCap":2240443},{"date":"2025-05-09","current":-0.219626,"twenty":-7.844246,"median":-0.210427,"eighty":-0.053454,"marketCap":2067433},{"date":"2025-05-16","current":-0.209957,"twenty":-7.844246,"median":-0.210015,"eighty":-0.053777,"marketCap":1856780},{"date":"2025-05-23","current":-0.222112,"twenty":-7.841083,"median":-0.211936,"eighty":-0.054087,"marketCap":1964278},{"date":"2025-05-30","current":-0.26967,"twenty":-7.836338,"median":-0.212746,"eighty":-0.054418,"marketCap":2384859},{"date":"2025-06-06","current":-0.348255,"twenty":-7.836338,"median":-0.216817,"eighty":-0.054599,"marketCap":3079838}],"updateTime":1749542810935}}}